Breast cancers that lack expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are categorized as triple-negative breast cancers (TNBCs), which comprise 10%–20% of all breast cancers. This evidence concerns the gene ESR1 and breast carcinoma.